{"product_id":"pfe-business-model-canvas","title":"Pfizer Inc. (PFE): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas gives you a clear, research-based view of how Pfizer Inc. creates value through drug discovery, Phase 2\/3 trials, global manufacturing, and commercial launch, supported by partnerships with Arvinas, Sarah Cannon Research Institute, Merck, regulators, and global suppliers. You'll see how Pfizer Inc. serves oncologists, hospitals, payers, public health buyers, vaccination providers, and patients in internal medicine and cardiometabolic care, while earning revenue from prescription drug sales, vaccine sales, COVID-19 product sales, royalties, and collaboration income. It also highlights the company's key resources, including branded medicines, vaccines, the oncology and obesity pipeline, the global network, Charlie AI, and cash flow for R\u0026amp;D, along with major cost drivers such as clinical trials, manufacturing, sales, restructuring, and tax and impairment charges.\u003c\/p\u003e\u003ch2\u003ePfizer Inc. - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003ePfizer's partnership structure in this canvas is built on external oncology science, trial access, regulatory approval, and supplier compliance. The key disclosed numbers here are \u003cstrong\u003e$650 million\u003c\/strong\u003e, \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e, \u003cstrong\u003e$43 billion\u003c\/strong\u003e, and \u003cstrong\u003e886\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArvinas oncology collaboration\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePfizer's collaboration with Arvinas centers on vepdegestrant, an estrogen receptor degrader for ER-positive, HER2-negative breast cancer. The disclosed economics were \u003cstrong\u003e$650 million\u003c\/strong\u003e upfront and up to \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e in milestones, which makes this one of Pfizer's clearest examples of paying for late-stage oncology access rather than building the program entirely in-house.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUpfront payment: \u003cstrong\u003e$650 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePotential milestones: \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAsset: vepdegestrant\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSarah Cannon Research Institute collaboration\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSarah Cannon Research Institute gives Pfizer access to community oncology trial sites. No public cash term is disclosed, so the partnership value is operational: faster patient enrollment, broader geography, and more real-world oncology patients than Pfizer would get from a small academic-only network.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePublic payment: Not disclosed\u003c\/li\u003e\n\u003cli\u003eSite model: community oncology\u003c\/li\u003e\n\u003cli\u003eBusiness value: enrollment speed\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMerck partnership on Padcev plus Keytruda trials\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePfizer's \u003cstrong\u003e$43 billion\u003c\/strong\u003e Seagen acquisition in 2023 brought Seagen's oncology economics into Pfizer, including Padcev, or enfortumab vedotin, in its partnership structure with Astellas. The Merck-linked trial program matters because the phase 3 EV-302\/KEYNOTE-A39 study enrolled \u003cstrong\u003e886\u003c\/strong\u003e patients in first-line locally advanced or metastatic urothelial cancer.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSeagen acquisition: \u003cstrong\u003e$43 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eEV-302\/KEYNOTE-A39 enrollment: \u003cstrong\u003e886\u003c\/strong\u003e patients\u003c\/li\u003e\n\u003cli\u003ePadcev partner: Astellas\u003c\/li\u003e\n\u003cli\u003eKeytruda owner: Merck\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulators and trial sites\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePfizer's development partnerships depend on regulatory approval and site activation. The main regulators in this chapter are the FDA, EMA, MHRA, and PMDA, and each one can affect trial timing, label timing, and launch timing.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNamed regulators: \u003cstrong\u003e4\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTrial-site payment: Not disclosed\u003c\/li\u003e\n\u003cli\u003eGatekeeping role: approvals and enrollment\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal suppliers with science-based targets\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePfizer's supplier partnerships depend on manufacturing continuity and emissions reporting. The external standard is the Science Based Targets initiative, and the operational point is that suppliers with measurable climate targets lower compliance and supply-risk pressure across a global pharma chain.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExternal standard: Science Based Targets initiative\u003c\/li\u003e\n\u003cli\u003eSupplier count with disclosed targets: Not disclosed\u003c\/li\u003e\n\u003cli\u003eOperational role: manufacturing continuity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership area\u003c\/th\u003e\n\u003cth\u003eReal-life numbers\u003c\/th\u003e\n\u003cth\u003ePfizer business-model role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eArvinas oncology collaboration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$650 million\u003c\/strong\u003e upfront; up to \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e milestones\u003c\/td\u003e\n\u003ctd\u003eExternal oncology pipeline access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSarah Cannon Research Institute collaboration\u003c\/td\u003e\n\u003ctd\u003ePublic payment not disclosed\u003c\/td\u003e\n\u003ctd\u003eCommunity oncology trial enrollment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeagen acquisition and Padcev partnership chain\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$43 billion\u003c\/strong\u003e acquisition in 2023; EV-302\/KEYNOTE-A39 enrolled \u003cstrong\u003e886\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eOwnership of Seagen economics; inherited participation in Padcev-related oncology collaborations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators and trial sites\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e named regulators: FDA, EMA, MHRA, PMDA\u003c\/td\u003e\n\u003ctd\u003eApproval and trial execution gatekeeping\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal suppliers with science-based targets\u003c\/td\u003e\n\u003ctd\u003eScience Based Targets initiative; supplier count not disclosed\u003c\/td\u003e\n\u003ctd\u003eSupply continuity and compliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003ePfizer Inc. - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$63.6B\u003c\/strong\u003e in 2024 revenue, \u003cstrong\u003e$58.5B\u003c\/strong\u003e in 2023 revenue, and \u003cstrong\u003e$43B\u003c\/strong\u003e for Seagen on \u003cstrong\u003eDecember 14, 2023\u003c\/strong\u003e frame the activity base for late 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey activity\u003c\/td\u003e\n\u003ctd\u003eReal-life number or amount\u003c\/td\u003e\n\u003ctd\u003eReal-life date or count\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug discovery and clinical development\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2\/3 pivotal trials\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,246\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEPIC-HR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2\/3 pivotal trials\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7,400+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMATISSE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2\/3 pivotal trials\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e37,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eolder-adult RSV phase 3 program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal manufacturing and supply optimization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$63.6B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal manufacturing and supply optimization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.5B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial launch and lifecycle management\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecember 14, 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial launch and lifecycle management\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eapproved Seagen medicines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI-enabled content supply chain\u003c\/td\u003e\n\u003ctd\u003eNot publicly disclosed\u003c\/td\u003e\n\u003ctd\u003eNot publicly disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDrug discovery and clinical development\u003c\/strong\u003e: \u003cstrong\u003e$10.8B\u003c\/strong\u003e in 2024 R\u0026amp;D expense.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePhase 2\/3 pivotal trials\u003c\/strong\u003e: \u003cstrong\u003e2,246\u003c\/strong\u003e, \u003cstrong\u003e7,400+\u003c\/strong\u003e, and \u003cstrong\u003e37,000+\u003c\/strong\u003e participants across major programs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGlobal manufacturing and supply optimization\u003c\/strong\u003e: \u003cstrong\u003e$63.6B\u003c\/strong\u003e in 2024 revenue and \u003cstrong\u003e$58.5B\u003c\/strong\u003e in 2023 revenue.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCommercial launch and lifecycle management\u003c\/strong\u003e: \u003cstrong\u003e$43B\u003c\/strong\u003e Seagen acquisition and \u003cstrong\u003e4\u003c\/strong\u003e approved oncology medicines.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAI-enabled content supply chain\u003c\/strong\u003e: no public numeric disclosure.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDecember 14, 2023\u003c\/strong\u003e - Seagen acquisition close.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$43B\u003c\/strong\u003e - transaction value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e - approved Seagen medicines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$63.6B\u003c\/strong\u003e - 2024 revenue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$58.5B\u003c\/strong\u003e - 2023 revenue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$10.8B\u003c\/strong\u003e - 2024 R\u0026amp;D expense.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2,246\u003c\/strong\u003e - EPIC-HR participants.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e7,400+\u003c\/strong\u003e - MATISSE participants.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e37,000+\u003c\/strong\u003e - older-adult RSV phase 3 participants.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003ePfizer Inc. - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$63.6B\u003c\/strong\u003e in 2024 revenue, \u003cstrong\u003e$10.8B\u003c\/strong\u003e in 2023 R\u0026amp;D spend, \u003cstrong\u003e$43.0B\u003c\/strong\u003e for Seagen, \u003cstrong\u003e4\u003c\/strong\u003e oncology medicines added, and \u003cstrong\u003e2\u003c\/strong\u003e obesity programs discontinued.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eResource\u003c\/td\u003e\n\u003ctd\u003eNumber\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$63.6B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 R\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeagen acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved oncology medicines added\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eObesity programs discontinued\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e disclosed active internal obesity candidates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCharlie AI platform\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e public user-count disclosure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial reach\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e125+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ecountries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePfizer branded medicines and vaccines\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e mRNA COVID-19 vaccine franchise\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e oral antiviral franchise\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e RSV vaccine franchise\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e pneumococcal vaccine franchise\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology and obesity pipeline\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e approved oncology medicines from Seagen\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$43.0B\u003c\/strong\u003e acquisition value\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e discontinued danuglipron programs\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e disclosed active internal obesity candidates\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal commercial and manufacturing network\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e125+\u003c\/strong\u003e countries\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e global network\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCharlie AI platform\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e internal AI platform\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e public user-count disclosure\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCash flow and R\u0026amp;D spend\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$63.6B\u003c\/strong\u003e 2024 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$10.8B\u003c\/strong\u003e 2023 R\u0026amp;D spend\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003ePfizer Inc. - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePfizer Inc.'s value proposition is built on approved medicines and vaccines that can scale globally. The clearest numbers are \u003cstrong\u003e$58.5B\u003c\/strong\u003e in 2023 revenue, \u003cstrong\u003e$100.3B\u003c\/strong\u003e in 2022 revenue, and the \u003cstrong\u003e$43B\u003c\/strong\u003e Seagen acquisition closed in 2023.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eValue proposition area\u003c\/th\u003e\n\u003cth\u003eReal-life numbers\u003c\/th\u003e\n\u003cth\u003eBusiness impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInnovative biopharmaceutical therapies\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$58.5B\u003c\/strong\u003e 2023 revenue; \u003cstrong\u003e$100.3B\u003c\/strong\u003e 2022 revenue\u003c\/td\u003e\n\u003ctd\u003eShows a large commercial base that supports continued R\u0026amp;D and launches\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccines for respiratory and infectious disease\u003c\/td\u003e\n\u003ctd\u003eABRYSVO 2023 approval; Penbraya 2023 approval\u003c\/td\u003e\n\u003ctd\u003eCreates recurring demand tied to immunization schedules and public health use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology treatments with new approvals\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$43B\u003c\/strong\u003e Seagen acquisition in 2023; Elrexfio 2023; Talzenna plus Xtandi 2023\u003c\/td\u003e\n\u003ctd\u003eExpands cancer depth and pipeline outside COVID products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge-scale global access and supply\u003c\/td\u003e\n\u003ctd\u003ePaxlovid licensing across \u003cstrong\u003e95\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eExtends reach through broader access and manufacturing pathways\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline-led growth beyond COVID products\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$100.3B\u003c\/strong\u003e to \u003cstrong\u003e$58.5B\u003c\/strong\u003e revenue shift from 2022 to 2023\u003c\/td\u003e\n\u003ctd\u003eShows why future growth depends on launches and pipeline execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovative biopharmaceutical therapies\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003ePfizer Inc. sells therapies that sit in high-value categories where approval, safety, and scale matter more than price alone. The company reported \u003cstrong\u003e$58.5B\u003c\/strong\u003e in 2023 revenue after \u003cstrong\u003e$100.3B\u003c\/strong\u003e in 2022, which shows how much the business model depends on moving from pandemic-led demand to a wider mix of approved products. That mix matters because one product line can fall fast, but a portfolio can replace lost sales with new launches.\u003c\/p\u003e\n\n\u003cp\u003eThe most important value proposition here is not a single drug. It is the ability to turn research into approved medicines across multiple categories, then sell them at global scale. The \u003cstrong\u003e$43B\u003c\/strong\u003e Seagen acquisition in 2023 is part of that strategy because it adds oncology assets to a broader biopharma base. For academic work, this is a clear example of portfolio diversification after a one-product revenue spike.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$58.5B\u003c\/strong\u003e 2023 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$100.3B\u003c\/strong\u003e 2022 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$43B\u003c\/strong\u003e Seagen acquisition\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eVaccines for respiratory and infectious disease\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eVaccines are one of Pfizer Inc.'s strongest value propositions because they address large patient groups and public health programs. ABRYSVO received 2023 approval for adults \u003cstrong\u003e60\u003c\/strong\u003e years and older, and the maternal indication covers pregnancy at \u003cstrong\u003e32\u003c\/strong\u003e to \u003cstrong\u003e36\u003c\/strong\u003e weeks of gestation. Penbraya received 2023 approval for individuals \u003cstrong\u003e10\u003c\/strong\u003e to \u003cstrong\u003e25\u003c\/strong\u003e years old. Those numbers show a broad age span, from adolescents to older adults.\u003c\/p\u003e\n\n\u003cp\u003eThis matters because respiratory and infectious disease vaccines are tied to seasonal demand, immunization recommendations, and repeat use. They also support the company's move away from COVID concentration. A vaccine franchise gives Pfizer Inc. a product type that can reach both routine prevention and higher-risk groups, which improves the chance of durable demand over time.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVaccine\u003c\/th\u003e\n\u003cth\u003eApproval year\u003c\/th\u003e\n\u003cth\u003eReal-life age or use group\u003c\/th\u003e\n\u003cth\u003eValue proposition\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eABRYSVO\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60\u003c\/strong\u003e+ years\u003c\/td\u003e\n\u003ctd\u003eRespiratory disease prevention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eABRYSVO\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e32\u003c\/strong\u003e to \u003cstrong\u003e36\u003c\/strong\u003e weeks gestation\u003c\/td\u003e\n\u003ctd\u003eMaternal immunization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePenbraya\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e to \u003cstrong\u003e25\u003c\/strong\u003e years\u003c\/td\u003e\n\u003ctd\u003eInfectious disease prevention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology treatments with new approvals\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eOncology is Pfizer Inc.'s clearest growth area beyond COVID products. The \u003cstrong\u003e$43B\u003c\/strong\u003e Seagen acquisition closed in 2023 and added cancer assets that strengthen the company's position in specialty oncology. Pfizer Inc. also secured 2023 approvals for Elrexfio and Talzenna plus Xtandi, which shows that the company is still adding approved treatments rather than relying only on acquisitions.\u003c\/p\u003e\n\n\u003cp\u003eThe value proposition in oncology is based on clinical differentiation, specialty prescribing, and pricing power. These products are used in high-acuity settings, so approval timing and label expansion can change revenue fast. In plain terms, one approved oncology drug can be worth far more than a standard primary care product because patients, doctors, and payers are dealing with serious disease and fewer treatment options.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$43B\u003c\/strong\u003e Seagen acquisition\u003c\/li\u003e\n\u003cli\u003eElrexfio approval in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTalzenna plus Xtandi approval in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLarge-scale global access and supply\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003ePfizer Inc.'s access proposition is not just about discovery. It is about distribution, licensing, and the ability to reach large populations. The company's Paxlovid licensing arrangement covered \u003cstrong\u003e95\u003c\/strong\u003e countries, which is a direct access number and shows how Pfizer Inc. can extend a medicine beyond a single high-income market.\u003c\/p\u003e\n\n\u003cp\u003eThat matters in academic analysis because access is part of the customer value, not a side issue. Governments, health systems, and global buyers need supply certainty, and Pfizer Inc.'s scale is visible in the jump from \u003cstrong\u003e$100.3B\u003c\/strong\u003e revenue in 2022 to \u003cstrong\u003e$58.5B\u003c\/strong\u003e in 2023. Even after the COVID peak, that scale still supports manufacturing, logistics, and broader geographic reach.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eAccess element\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eBusiness meaning\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePaxlovid licensing territories\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e95\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eBroader access through licensing and manufacturing pathways\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100.3B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows peak scale during pandemic demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.5B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows the size of the post-peak base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePipeline-led growth beyond COVID products\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003ePfizer Inc.'s long-term value proposition now depends on pipeline-led growth rather than pandemic products alone. The revenue move from \u003cstrong\u003e$100.3B\u003c\/strong\u003e in 2022 to \u003cstrong\u003e$58.5B\u003c\/strong\u003e in 2023 is the clearest sign of that shift. When one revenue source falls that sharply, the company has to replace it with launches, label expansions, and deal making.\u003c\/p\u003e\n\n\u003cp\u003eThat is why the \u003cstrong\u003e$43B\u003c\/strong\u003e Seagen acquisition matters so much. It gives Pfizer Inc. more oncology depth while 2023 approvals such as ABRYSVO, Penbraya, Elrexfio, and Talzenna plus Xtandi keep the launch pipeline active. For a business model canvas, this value proposition shows how Pfizer Inc. turns regulatory approvals and transactions into future revenue streams.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$100.3B\u003c\/strong\u003e 2022 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$58.5B\u003c\/strong\u003e 2023 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$43B\u003c\/strong\u003e Seagen acquisition\u003c\/li\u003e\n\u003cli\u003eABRYSVO approval in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePenbraya approval in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eElrexfio approval in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTalzenna plus Xtandi approval in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003ePfizer Inc. - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003ePfizer's customer relationships are mostly B2B and evidence-led. As of late 2025, the model is anchored by \u003cstrong\u003e$63.6B\u003c\/strong\u003e in 2024 revenue and \u003cstrong\u003e$10.8B\u003c\/strong\u003e in 2024 R\u0026amp;D spending, so access, trust, and reimbursement matter more than consumer-style loyalty.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D spending was about \u003cstrong\u003e17%\u003c\/strong\u003e of revenue in 2024 (\u003cstrong\u003e$10.8B\u003c\/strong\u003e divided by \u003cstrong\u003e$63.6B\u003c\/strong\u003e), which shows why scientific evidence is part of the customer relationship, not just a support function.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer relationship layer\u003c\/th\u003e\n\u003cth\u003eMain counterparties\u003c\/th\u003e\n\u003cth\u003eWhat they require\u003c\/th\u003e\n\u003cth\u003ePfizer relationship method\u003c\/th\u003e\n\u003cth\u003eBusiness effect\u003c\/th\u003e\n\u003cth\u003eRelevant data point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician and specialist engagement\u003c\/td\u003e\n\u003ctd\u003eOncologists, cardiologists, infectious disease physicians, neurologists, pharmacists\u003c\/td\u003e\n\u003ctd\u003eClinical efficacy, safety, dosing, patient selection\u003c\/td\u003e\n\u003ctd\u003eMedical science liaisons, congresses, publications, advisory boards\u003c\/td\u003e\n\u003ctd\u003eSupports prescribing and guideline adoption\u003c\/td\u003e\n\u003ctd\u003e2024 revenue \u003cstrong\u003e$63.6B\u003c\/strong\u003e; 2024 R\u0026amp;D \u003cstrong\u003e$10.8B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital and health-system contracting\u003c\/td\u003e\n\u003ctd\u003eHospitals, integrated delivery networks, group purchasing organizations, pharmacy and therapeutics committees\u003c\/td\u003e\n\u003ctd\u003eFormulary fit, supply reliability, budget impact\u003c\/td\u003e\n\u003ctd\u003eTenders, contracting, service support, supply planning\u003c\/td\u003e\n\u003ctd\u003eInfluences access, volume, and switching\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D intensity about \u003cstrong\u003e17%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term payer and government relationships\u003c\/td\u003e\n\u003ctd\u003eCommercial insurers, PBMs, Medicare, Medicaid, government buyers\u003c\/td\u003e\n\u003ctd\u003eReimbursement, price, coverage, value evidence\u003c\/td\u003e\n\u003ctd\u003eNegotiation, rebate structures, health economic data\u003c\/td\u003e\n\u003ctd\u003eDetermines net price and patient access\u003c\/td\u003e\n\u003ctd\u003e2024 revenue \u003cstrong\u003e$63.6B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical affairs and evidence support\u003c\/td\u003e\n\u003ctd\u003eClinicians, pharmacists, policy makers, health-system leaders\u003c\/td\u003e\n\u003ctd\u003eIndependent scientific information, safety data, real-world evidence\u003c\/td\u003e\n\u003ctd\u003eMedical information, publications, post-approval studies\u003c\/td\u003e\n\u003ctd\u003eProtects trust and supports label use\u003c\/td\u003e\n\u003ctd\u003e2024 R\u0026amp;D \u003cstrong\u003e$10.8B\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership-based research collaboration\u003c\/td\u003e\n\u003ctd\u003eBiotech firms, academic centers, CROs, hospital networks\u003c\/td\u003e\n\u003ctd\u003eDevelopment funding, trial capability, asset sharing\u003c\/td\u003e\n\u003ctd\u003eLicensing, co-development, sponsored research\u003c\/td\u003e\n\u003ctd\u003eSpreads risk and expands pipeline options\u003c\/td\u003e\n\u003ctd\u003e2024 R\u0026amp;D \u003cstrong\u003e$10.8B\u003c\/strong\u003e; R\u0026amp;D about \u003cstrong\u003e17%\u003c\/strong\u003e of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePhysician and specialist engagement is the core relationship layer for prescription medicines. Pfizer does not sell only on brand awareness; it wins by matching clinical evidence to specialist decision-making, especially in oncology, vaccines, cardiology, infectious disease, and rare disease. That matters because these are areas where treatment choice depends on trial design, safety profile, patient subgroup data, and dosing convenience.\u003c\/p\u003e\n\u003cp\u003eIn practice, the relationship is built through scientific exchange, not consumer marketing. Medical science liaisons answer technical questions, publish and discuss trial data, and help specialists interpret new evidence. Congresses and peer-reviewed publications matter because they shape adoption before and after inclusion in local treatment guidelines. This is important for a company with \u003cstrong\u003e$63.6B\u003c\/strong\u003e in annual revenue, because small changes in specialist confidence can move large prescription volumes.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSpecialists care about efficacy, safety, and patient selection before they care about price.\u003c\/li\u003e\n\u003cli\u003eClinical trial design affects trust because physicians compare endpoints, follow-up length, and subgroup results.\u003c\/li\u003e\n\u003cli\u003eLabel familiarity matters because specialists prefer products with clear dosing and manageable monitoring.\u003c\/li\u003e\n\u003cli\u003eAcademic detailing matters because it keeps the relationship centered on data instead of promotion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHospital and health-system contracting is a separate layer from individual physician engagement. Hospitals, integrated delivery networks, group purchasing organizations, and pharmacy and therapeutics committees decide whether a product gets preferred access, restricted access, or no broad use. For Pfizer, this is especially important in injectable, infused, and hospital-administered products, where the buyer is often the institution rather than the end patient.\u003c\/p\u003e\n\u003cp\u003eThe commercial relationship here is shaped by acquisition cost, administration burden, storage requirements, supply reliability, and budget impact. A hospital may like the clinical data but still reject a product if the cost structure is too high or the logistics are weak. That is why Pfizer has to combine contracting discipline with dependable supply and service support. In this part of the model, relationship quality shows up as formulary placement and repeat procurement, not just physician sentiment.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFormulary access can matter more than direct physician promotion in institutional care.\u003c\/li\u003e\n\u003cli\u003eBudget holders focus on total cost of care, not only list price.\u003c\/li\u003e\n\u003cli\u003eSupply continuity is critical because stockouts can force switching and damage trust.\u003c\/li\u003e\n\u003cli\u003eHealth-system decisions often create multi-site access at once, so one contract can affect many patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLong-term payer and government relationships determine how much of Pfizer's gross sales turn into usable revenue. Payers include commercial insurers and pharmacy benefit managers, while government buyers include Medicare, Medicaid, and procurement agencies. These counterparties care about coverage rules, rebates, prior authorization, step therapy, and the evidence that a product improves outcomes relative to cost.\u003c\/p\u003e\n\u003cp\u003eThis relationship is long term because reimbursement decisions repeat every year or every contract cycle. If a payer removes preferred status, access can fall fast even if physicians support the product. If a government buyer negotiates a lower net price, access can rise but pricing pressure increases. Pfizer has to balance those trade-offs across a global portfolio, which is why health economic data is part of customer relationships, not an afterthought.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCoverage decisions can determine whether a patient can start treatment without delay.\u003c\/li\u003e\n\u003cli\u003eRebate and contracting structures affect net realized price, not just list price.\u003c\/li\u003e\n\u003cli\u003eGovernment relationships can provide scale but usually come with tighter price discipline.\u003c\/li\u003e\n\u003cli\u003eEconomic evidence matters because payers compare clinical benefit against cost per patient.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMedical affairs is the trust layer that keeps Pfizer's scientific relationships credible. It is different from sales because its role is to provide medical information, safety updates, publication support, and post-approval evidence. This matters in regulated healthcare markets where clinicians, payers, and policy makers expect unbiased scientific support.\u003c\/p\u003e\n\u003cp\u003eMedical affairs also supports real-world evidence generation, which means data collected after approval in routine practice. That evidence can support label expansion, payer discussions, and hospital adoption. With \u003cstrong\u003e$10.8B\u003c\/strong\u003e in 2024 R\u0026amp;D spending, Pfizer is not just funding discovery; it is funding the evidence base that lets customers decide with confidence. In business model terms, medical affairs helps convert science into access and access into revenue.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMedical information requests help clinicians use a product correctly.\u003c\/li\u003e\n\u003cli\u003eSafety monitoring protects trust after launch.\u003c\/li\u003e\n\u003cli\u003eReal-world evidence helps show how a product performs outside a trial.\u003c\/li\u003e\n\u003cli\u003ePublication strategy matters because peer-reviewed data carries weight with specialists and payers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePartnership-based research collaboration extends Pfizer's customer relationships into the development stage. The company works with biotech firms, academic centers, contract research organizations, and hospital networks to co-develop assets, run trials, and access specialized expertise. This matters because many future customers are first encountered as investigators, trial sites, or scientific collaborators.\u003c\/p\u003e\n\u003cp\u003eThese collaborations reduce development risk and broaden access to new science. They also create early credibility with specialist communities because the physicians and institutions involved in trials often become downstream adopters. The financial signal is Pfizer's 2024 R\u0026amp;D intensity of about \u003cstrong\u003e17%\u003c\/strong\u003e of revenue, which shows that collaboration is funded at scale rather than treated as a side activity. In late 2025, this part of the customer relationship model remains central to pipeline renewal.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCo-development helps spread scientific and financial risk.\u003c\/li\u003e\n\u003cli\u003eAcademic collaboration helps recruit investigators and trial sites.\u003c\/li\u003e\n\u003cli\u003eBiotech partnerships can give Pfizer access to platforms or molecules it does not own internally.\u003c\/li\u003e\n\u003cli\u003eCollaborative trials can speed learning in complex areas such as oncology and immunology.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003ePfizer Inc. - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eAs of late 2025, Pfizer Inc. uses a multi-channel model built around U.S. field sales, international affiliates, specialty and hospital distribution, retail pharmacy access for vaccines, and selective partnerships. The mix fits prescription medicines and vaccines that need prescriber approval, payer access, cold-chain handling, and institutional purchasing.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eU.S. commercial organization\u003c\/strong\u003e Pfizer Inc. reaches the U.S. market through commercial teams that work with physicians, health systems, payers, wholesalers, specialty pharmacies, and hospitals. The channel is built for prescription demand, not direct consumer selling. Access depends on formulary placement, reimbursement, and account-level contracting, because a formulary is the approved drug list used by insurers and hospitals. This channel matters most for chronic therapies, specialty medicines, and vaccines that need broad insurance coverage and repeat ordering.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eLarge wholesalers\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacies\u003c\/li\u003e\n\u003cli\u003eHospital systems\u003c\/li\u003e\n\u003cli\u003ePhysician offices\u003c\/li\u003e\n\u003cli\u003ePayers and pharmacy benefit managers\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInternational commercial organization\u003c\/strong\u003e Outside the U.S., Pfizer Inc. uses country affiliates, distributors, tender sales, and local market access teams. A tender is a competitive bid for a government or hospital supply contract. That channel is important in public healthcare systems where ministries of health and state hospitals buy in bulk instead of through individual prescriptions. The international route also adapts to local pricing rules, import controls, language, and reimbursement systems. In many markets, the commercial team is smaller than in the U.S., so partner capability and regulatory execution carry more weight.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCountry affiliates\u003c\/li\u003e\n\u003cli\u003eLocal distributors\u003c\/li\u003e\n\u003cli\u003eGovernment tenders\u003c\/li\u003e\n\u003cli\u003ePublic hospital systems\u003c\/li\u003e\n\u003cli\u003ePrivate payer networks\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialty and hospital distribution\u003c\/strong\u003e Pfizer Inc. uses specialty distributors, specialty pharmacies, group purchasing organizations, and integrated delivery networks for oncology and hospital products. Integrated delivery networks are hospital systems that buy and manage care as one organization. Group purchasing organizations negotiate buying terms for many hospitals at once. These channels matter because specialty products often need temperature control, prior authorization, injection support, or inpatient use. The commercial focus is supply reliability, contract access, and formulary placement, not mass promotion. For academic work, this is the clearest example of institutional buying in pharmaceuticals.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003ePrimary customer\u003c\/th\u003e\n\u003cth\u003eAccess route\u003c\/th\u003e\n\u003cth\u003eProduct fit\u003c\/th\u003e\n\u003cth\u003eChannel role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. commercial organization\u003c\/td\u003e\n\u003ctd\u003ePhysicians, payers, wholesalers, specialty pharmacies, hospitals\u003c\/td\u003e\n \u003ctd\u003eField teams, reimbursement support, contracting\u003c\/td\u003e\n \u003ctd\u003ePrescription medicines, specialty medicines, vaccines\u003c\/td\u003e\n \u003ctd\u003eDrives prescribing and coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational commercial organization\u003c\/td\u003e\n\u003ctd\u003eCountry regulators, ministries of health, hospitals, distributors\u003c\/td\u003e\n \u003ctd\u003eAffiliates, tenders, local partners\u003c\/td\u003e\n\u003ctd\u003ePrescription medicines, vaccines\u003c\/td\u003e\n\u003ctd\u003eFits local pricing and procurement rules\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty and hospital distribution\u003c\/td\u003e\n\u003ctd\u003eSpecialty pharmacies, hospital systems, group purchasing organizations\u003c\/td\u003e\n \u003ctd\u003eControlled distribution, hospital contracts\u003c\/td\u003e\n \u003ctd\u003eOncology, hospital medicines, sterile products\u003c\/td\u003e\n \u003ctd\u003eSupports handling and institutional access\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccine and retail pharmacy networks\u003c\/td\u003e\n\u003ctd\u003eRetail chains, independent pharmacies, clinics, public programs\u003c\/td\u003e\n \u003ctd\u003ePharmacy stocking, seasonal programs, public purchasing\u003c\/td\u003e\n \u003ctd\u003eAdult and pediatric vaccines\u003c\/td\u003e\n\u003ctd\u003eReaches high-volume immunization demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic partnership and channel development\u003c\/td\u003e\n \u003ctd\u003eBiotech partners, governments, licensees\u003c\/td\u003e\n \u003ctd\u003eCo-promotion, licensing, supply agreements\u003c\/td\u003e\n \u003ctd\u003eSelect therapies and geographies\u003c\/td\u003e\n\u003ctd\u003eExpands reach without full in-house build\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eVaccine and retail pharmacy networks\u003c\/strong\u003e Pfizer Inc. uses retail pharmacy chains, independent pharmacies, clinics, wholesalers, and public-health programs for vaccines. This channel works because vaccination demand is seasonal, high volume, and often convenience-based. Adults usually get shots where they already buy medicines, so pharmacy access matters more than hospital access. Public programs matter because they expand coverage to children and uninsured patients. Vaccine channels also require cold-chain discipline, which makes logistics part of the channel, not a back-office task.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eRetail pharmacy chains\u003c\/li\u003e\n\u003cli\u003eIndependent pharmacies\u003c\/li\u003e\n\u003cli\u003ePrimary care clinics\u003c\/li\u003e\n\u003cli\u003ePublic health programs\u003c\/li\u003e\n\u003cli\u003eHospital vaccination sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrategic partnership and channel development\u003c\/strong\u003e Pfizer Inc. expands channels through partnerships where it does not want to build full local sales, logistics, or hospital access on its own. The biggest recent example is the \u003cstrong\u003e$43 billion\u003c\/strong\u003e acquisition of Seagen, completed on \u003cstrong\u003eDecember 14, 2023\u003c\/strong\u003e, which strengthened Pfizer Inc.'s oncology presence in specialty and hospital channels. Partnerships in this industry also include co-promotion, licensing, and supply agreements with governments and local distributors. These structures matter because they shorten time to market, widen geographic coverage, and improve access to hard-to-reach institutions.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eStrategic event\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eChannel effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeagen acquisition\u003c\/td\u003e\n\u003ctd\u003e$43 billion\u003c\/td\u003e\n\u003ctd\u003eDecember 14, 2023\u003c\/td\u003e\n\u003ctd\u003eExpanded oncology specialty and hospital channels\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eChannel economics\u003c\/strong\u003e Pfizer Inc. sells through channels that settle at different net prices after rebates, chargebacks, and contract discounts. A rebate is a post-sale payment that lowers the final price. That matters because gross sales and net sales can differ materially in pharmaceuticals, especially for products that pass through wholesalers, pharmacies, and government programs. Channel design therefore affects revenue quality, not just reach.\u003c\/p\u003e\n\u003ch2\u003ePfizer Inc. - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer segment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life numbers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer setting\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncologists and cancer patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20,000,000\u003c\/strong\u003e; \u003cstrong\u003e9,700,000\u003c\/strong\u003e; \u003cstrong\u003e2,001,140\u003c\/strong\u003e; \u003cstrong\u003e611,720\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eoncology clinics; academic centers; hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccination providers and eligible adults\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6 months\u003c\/strong\u003e; \u003cstrong\u003e18\u003c\/strong\u003e; \u003cstrong\u003e50\u003c\/strong\u003e; \u003cstrong\u003e9,300,000\u003c\/strong\u003e to \u003cstrong\u003e41,000,000\u003c\/strong\u003e; \u003cstrong\u003e140,000\u003c\/strong\u003e to \u003cstrong\u003e710,000\u003c\/strong\u003e; \u003cstrong\u003e12,000\u003c\/strong\u003e to \u003cstrong\u003e52,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eretail pharmacies; physician offices; health systems; public clinics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and health systems\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6,120\u003c\/strong\u003e; \u003cstrong\u003e5,129\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003einpatient and outpatient care networks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers and public health buyers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e66,000,000+\u003c\/strong\u003e; \u003cstrong\u003e51\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMedicare; state and federal public health programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients for internal medicine and cardiometabolic care\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e537,000,000\u003c\/strong\u003e; \u003cstrong\u003e1,280,000,000\u003c\/strong\u003e; \u003cstrong\u003e38,400,000\u003c\/strong\u003e; \u003cstrong\u003e97,600,000\u003c\/strong\u003e; \u003cstrong\u003e17,900,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eprimary care; cardiology; endocrinology; chronic care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncologists and cancer patients\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e20,000,000\u003c\/strong\u003e new cancer cases worldwide in 2022\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e9,700,000\u003c\/strong\u003e cancer deaths worldwide in 2022\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2,001,140\u003c\/strong\u003e new cancer cases in the United States in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e611,720\u003c\/strong\u003e cancer deaths in the United States in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eVaccination providers and eligible adults\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e6 months\u003c\/strong\u003e and older\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e18\u003c\/strong\u003e years and older\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e50\u003c\/strong\u003e years and older\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e9,300,000\u003c\/strong\u003e to \u003cstrong\u003e41,000,000\u003c\/strong\u003e influenza illnesses annually in the United States\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e140,000\u003c\/strong\u003e to \u003cstrong\u003e710,000\u003c\/strong\u003e influenza hospitalizations annually in the United States\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12,000\u003c\/strong\u003e to \u003cstrong\u003e52,000\u003c\/strong\u003e influenza deaths annually in the United States\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospitals and health systems\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e6,120\u003c\/strong\u003e hospitals in the United States\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e5,129\u003c\/strong\u003e community hospitals in the United States\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePayers and public health buyers\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e66,000,000+\u003c\/strong\u003e Medicare beneficiaries\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e51\u003c\/strong\u003e U.S. jurisdictions\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatients for internal medicine and cardiometabolic care\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e537,000,000\u003c\/strong\u003e adults aged 20 to 79 with diabetes worldwide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,280,000,000\u003c\/strong\u003e adults aged 30 to 79 with hypertension worldwide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e38,400,000\u003c\/strong\u003e people with diabetes in the United States\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e97,600,000\u003c\/strong\u003e U.S. adults with prediabetes\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e17,900,000\u003c\/strong\u003e cardiovascular deaths worldwide each year\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003ePfizer Inc. - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003ePfizer Inc.'s 2024 cost base was dominated by \u003cstrong\u003e$10.8 billion\u003c\/strong\u003e of research and development, with cost of sales at \u003cstrong\u003e$19.0 billion\u003c\/strong\u003e and selling, informational and administrative expense at \u003cstrong\u003e$13.8 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost line\u003c\/td\u003e\n\u003ctd\u003e2024 amount\u003c\/td\u003e\n\u003ctd\u003eShare of $63.6 billion revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of sales\u003c\/td\u003e\n\u003ctd\u003e$19.0 billion\u003c\/td\u003e\n\u003ctd\u003e29.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003ctd\u003e$10.8 billion\u003c\/td\u003e\n\u003ctd\u003e17.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, informational and administrative\u003c\/td\u003e\n\u003ctd\u003e$13.8 billion\u003c\/td\u003e\n\u003ctd\u003e21.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmortization of intangible assets\u003c\/td\u003e\n\u003ctd\u003e$4.5 billion\u003c\/td\u003e\n\u003ctd\u003e7.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring and other charges\u003c\/td\u003e\n\u003ctd\u003e$1.2 billion\u003c\/td\u003e\n\u003ctd\u003e1.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncome tax expense\u003c\/td\u003e\n\u003ctd\u003e$2.0 billion\u003c\/td\u003e\n\u003ctd\u003e3.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D and clinical trial spend\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$10.8 billion\u003c\/strong\u003e of research and development expense in 2024 equals \u003cstrong\u003e17.0%\u003c\/strong\u003e of \u003cstrong\u003e$63.6 billion\u003c\/strong\u003e revenue. In a pharmaceutical model, this is the cost of pipeline renewal, late-stage studies, regulatory work, and post-approval development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$10.8 billion\u003c\/strong\u003e research and development expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e17.0%\u003c\/strong\u003e of revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$63.6 billion\u003c\/strong\u003e total revenue base\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and network optimization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$19.0 billion\u003c\/strong\u003e of cost of sales in 2024 captures manufacturing, packaging, freight, and product supply costs. This line is the main measure of production efficiency because it sits directly against revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$19.0 billion\u003c\/strong\u003e cost of sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e29.9%\u003c\/strong\u003e of revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.5 billion\u003c\/strong\u003e amortization of intangible assets\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.2 billion\u003c\/strong\u003e restructuring and other charges\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSales, marketing, and distribution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$13.8 billion\u003c\/strong\u003e of selling, informational and administrative expense in 2024 equals \u003cstrong\u003e21.7%\u003c\/strong\u003e of revenue. This is the cost of commercial teams, promotion, digital outreach, customer support, and corporate overhead tied to market access and product uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$13.8 billion\u003c\/strong\u003e selling, informational and administrative expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e21.7%\u003c\/strong\u003e of revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$63.6 billion\u003c\/strong\u003e revenue base\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCost realignment and restructuring\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$1.2 billion\u003c\/strong\u003e of restructuring and other charges in 2024 shows the scale of footprint and organization changes inside the cost base. On a revenue base of \u003cstrong\u003e$63.6 billion\u003c\/strong\u003e, that equals \u003cstrong\u003e1.9%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.2 billion\u003c\/strong\u003e restructuring and other charges\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1.9%\u003c\/strong\u003e of revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$63.6 billion\u003c\/strong\u003e revenue base\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTax and impairment-related charges\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$2.0 billion\u003c\/strong\u003e of income tax expense and \u003cstrong\u003e$4.5 billion\u003c\/strong\u003e of amortization of intangible assets sit alongside the operating cost base. These charges matter because they reduce reported profit even when cash spending is lower than accounting expense.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.0 billion\u003c\/strong\u003e income tax expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3.1%\u003c\/strong\u003e of revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.5 billion\u003c\/strong\u003e amortization of intangible assets\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e7.1%\u003c\/strong\u003e of revenue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003ePfizer Inc. - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$63.6B\u003c\/strong\u003e in 2024 revenue versus \u003cstrong\u003e$58.5B\u003c\/strong\u003e in 2023, a change of \u003cstrong\u003e$5.1B\u003c\/strong\u003e and \u003cstrong\u003e8.7%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue stream\u003c\/td\u003e\n\u003ctd\u003eReal-life numeric fact\u003c\/td\u003e\n\u003ctd\u003eRelated item\u003c\/td\u003e\n\u003ctd\u003eAdditional numeric fact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription drug sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$63.6B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.5B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccine sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eComirnaty\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50\/50\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID-19 product sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eComirnaty, Paxlovid\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties and collaboration revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50\/50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEliquis\u003c\/td\u003e\n\u003ctd\u003eBristol Myers Squibb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational and U.S. product revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S., international\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eComirnaty used a \u003cstrong\u003e50\/50\u003c\/strong\u003e profit-and-loss split with BioNTech.\u003c\/p\u003e\n\u003cp\u003eEliquis used a \u003cstrong\u003e50\/50\u003c\/strong\u003e profit-sharing arrangement with Bristol Myers Squibb.\u003c\/p\u003e\n\u003cp\u003eCOVID-19 product sales came from \u003cstrong\u003e2\u003c\/strong\u003e products.\u003c\/p\u003e\n\u003cp\u003ePfizer reported revenue across \u003cstrong\u003e2\u003c\/strong\u003e geographic buckets: the U.S. and international markets.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$63.6B\u003c\/strong\u003e 2024 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$58.5B\u003c\/strong\u003e 2023 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.1B\u003c\/strong\u003e year-over-year increase\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e8.7%\u003c\/strong\u003e year-over-year growth\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e COVID-19 products\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e50\/50\u003c\/strong\u003e Comirnaty split with BioNTech\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e50\/50\u003c\/strong\u003e Eliquis split with Bristol Myers Squibb\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e geographic revenue buckets\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601617285269,"sku":"pfe-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/pfe-business-model-canvas.png?v=1740205695","url":"https:\/\/dcf-analysis.com\/products\/pfe-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}